• Sofdra (sofpironium) topical gel sales grew 171% to 45,769 prescriptions
• Expanded sales force from 27 to 50 professionals to drive continued growth
• Exploring API supply chain optimization to reduce cost of goods sold by 25-40%

Botanix Pharmaceuticals Limited (ASX:BOT) reported its half-year results for the period ended 31 December 2025. The company incurred a net loss of $33.2 million, up 7.5% from the prior corresponding period, as it ramped up Sofdra sales and marketing efforts. Revenue from Sofdra sales grew 4,675% to $16.5 million, driven by a 171% increase in total prescriptions shipped to 45,769. The company completed the planned expansion of its sales force from 27 to 50 professionals, including highly experienced individuals who have launched over 100 products. Sofdra adherence continues to exceed industry benchmarks, and the company's fulfillment platform has driven improvements in gross-to-net yield. Market research showed 90% of healthcare providers expect to increase Sofdra prescribing in the next six months. Botanix is focused on securing alternative API suppliers to reduce cost of goods sold by 25-40%, as well as expanding Sofdra licensing to other regions. The company also announced a $45 million capital raise to support its growth initiatives.

The company is guiding for continued strong sales growth of Sofdra (sofpironium) topical gel in the coming quarters. Botanix is also exploring API supply chain optimization to reduce cost of goods sold by 25-40% over the long term.

Botanix remains well-positioned for growth, with plans to deliver continued Sofdra sales growth, add new products to its fulfillment platform, secure API supply, expand Sofdra licensing, and pursue strategic mergers and acquisitions.